

Link to Order: [http://fivephoton.com/index.php?route=product/product&path=37&product\\_id=56](http://fivephoton.com/index.php?route=product/product&path=37&product_id=56)

Price: \$119.95

Website: www.fivephoton.com. Tel: 800-462-4507

---

## **PHARMACOPHORE PERCEPTION, DEVELOPMENT, AND USE IN DRUG DESIGN**

edited by

**OSMAN F. GÜNER**

### **Table of Contents:**

Preface xv

List of Contributors xxi

### **Part I. THE ORIGINS OF PHARMACOPHORE RESEARCH 1**

#### **1. Evolution of the Pharmacophore Concept in Pharmaceutical Research 3**

*Peter Gund*

### **Part II. ANALOG-BASED PHARMACOPHORES 13**

#### **2. Manual Pharmacophore Generation: Visual Pattern Recognition 17**

*Osman F. Güner*

#### **3. Pharmacophore Definition Using the Active Analog Approach 21**

*Denise D. Beusen and Garland R. Marshall*

3.1. Introduction 23

3.2. The Active Analog Approach 24

3.3. Systematic Search and the Rigid Geometry Approximation 26

3.4. Combinatorial Nature of Systematic Search 26

3.5. Strategies for Defeating the Combinatorial Explosion 27

3.5.1. Rigid Body Rotations and Building Molecules from Aggregates 27

3.5.2. Look-Ahead 31

3.5.3. Energy Filtering 31

3.5.4. Ping Closures 31

3.6. Systematic Search Parameters Which Impact Sampling Completeness 33

3.7. Analysis of Datasets 38

3.8. Considerations in Using the Active Analog Approach 39

3.8.1. Pharmacophore vs. Active-Site Models 39

3.8.2. Selection of Molecules for Analysis 40

3.8.3. Interpreting the Results 40

3.9. Examples of the Application of the Active Analog Approach 41

3.9.1. Morphiceptin Analogs 41

3.9.2. ACE Inhibitors 42

3.9.3. Substance P Antagonists 43

### **Automated Pharmacophore Development Systems 47**

#### **4. DISCO: What We Did Right and What We Missed 49**

*Yvonne Connolly Martin*

4.1. Overview of DISCO 51

4.2. The Problem of Searching for Correspondences 54

4.3. The Importance of Conformational Searching 55

4.4. Selecting the Conformational Ensemble 56

4.5. Selecting Compounds for the DISCO Analysis 58

- 4.6. What DISCO Uses as Points to Match **60**
- 4.7. Tolerance: The Trade-Off Between a Close Match and Including More Points  
**61**
- 4.8. Typical Outcomes and Strategies for Follow-Up **62**
- 4.9. Shortcomings in DISCO **63**
- 4.10. DISCO in the Age of HTS and Molecular Diversity **64**
- 5. HipHop: Pharmacophores Based on Multiple Common-Feature Alignments**  
**69**  
*Omoshile O. Clement and Adrea Trope Mehl*
- 5.1. Background **71**
- 5.2. Methodology **72**
  - 5.2.1. General Considerations 72
  - 5.2.2. Algorithm 73
  - 5.2.3. Choosing Relevant Conformations 73
  - 5.2.4. Feature Definition 74
  - 5.2.5. Generating Common Feature Hypotheses Using HipHop 74
  - 5.2.6. Input Conformers 75
  - 5.2.7. Parameter Setting 75
- 5.3. Applications **77**
  - 5.3.1. 5HTP-3 Antagonists 77
  - 5.3.2. ETA Endothelin Antagonists 79
  - 5.3.3. HIV-1 Protease Inhibitors 79
- 5.4. Conclusion **82**
- 6. GASP: Genetic Algorithm Superimposition Program 85**  
*Gareth Jones and Peter Willett*
- 6.1. Introduction **87**
- 6.2. The Chromosome Representation and the Genetic Operators **89**
  - 6.2.1. Input of 3D Structures 89
  - 6.2.2. Chromosome Representation 90
  - 6.2.3. Genetic Operators 91
- 6.3. The Fitness Function **92**
  - 6.3.1. Generation of Conformations and Least-Squares Fitting 93
  - 6.3.2. Calculation of the van der Waals Energy 94
  - 6.3.3. Calculation of the Volume Integral 94
  - 6.3.4. Calculation of the Similarity Score 95
- 6.4. Identification of Pharmacophores Using GASP **101**
  - 6.4.1. Leu-Enkephalin and a Hybrid Morphine 101
  - 6.4.2. Overlay of Four 5-HT3 Antagonists 102
  - 6.4.3. Overlay of Six Angiotensin II Receptor Antagonists 103
- 6.5. Conclusion **104**
- 7. Exploring Pharmacophores with Chem-X 107**  
*Stephen J. Cato*
- 7.1. Introduction **109**
- 7.2. Centers in Chem-X **110**
- 7.3. Centers in 3D Searching **111**
- 7.4. Pharmacophore Keys Defined **114**

7.5.	Generating Pharmacophore Keys	117
7.6.	Working with Pharmacophore Keys	119
7.7.	Pharmacophore Diversity	121
7.8.	Virtual Screening	123
7.9.	Diamond Pharmacophores	124
<b>Predictive Model Development—3D QSAR</b>		<b>127</b>
<b>8.</b>	<b>Apex-3D: Activity Prediction Expert System with 3D QSAR</b>	<b>129</b>
<i>Erich R. Vorpapel and Valery E. Golender</i>		
8.1.	Introduction	131
8.2.	General Description of Apex-3D	133
8.3.	Steroid Binding Data	136
8.4.	Conformer Generation Strategy	137
8.5.	Activity Classification Analysis	138
8.5.1.	Pharmacophores Identified	140
8.5.2.	Prediction (Classification) Results	141
8.6.	3D QSAR Models	141
8.6.1.	Testosterone-Binding 3D QSAR Model	142
8.6.2.	Corticosteroid 3D QSAR Model	144
8.7.	Comparison with other 3D QSAR Methods	145
8.8.	Conclusions	147
<b>9.</b>	<b>Pharmacophore Models and Comparative Molecular Field Analysis (CoMFA)</b>	<b>151</b>
<i>Robert D. Clark, Joseph M. Leonard, and Alexander Strizhev</i>		
9.1.	What Is CoMFA?	153
9.2.	Alignment Rules	155
9.3.	The s Receptor Dataset	156
9.4.	Charges and Energy Minimization	159
9.5.	Identifying an Initial Query	160
9.6.	Refining the Query	162
9.7.	Evaluating the Model	163
9.8.	Applicability	166
<b>10.</b>	<b>HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models</b>	<b>171</b>
<i>Hong Li, Jon Sutter, and Rémy Hoffmann</i>		
10.1.	Introduction	173
10.2.	General Strategy	174
10.3.	Methodology	175
10.3.1.	Preparing to Run HypoGen	176
10.3.2.	Running HypoGen	179
10.4.	Case Study	179
10.5.	Conclusion	187
<b>Applications in Drug Design</b>		<b>191</b>
<b>11.</b>	<b>Metric for Analyzing Hit Lists and Pharmacophores</b>	<b>193</b>
<i>Osman F. Güner and Douglas R. Henry</i>		
11.1.	Introduction	195
11.2.	Results and Discussion	196

11.2.1.	Application Examples	205
11.3.	Conclusions	<b>210</b>
<b>12.</b>	<b>Strategies for Database Mining and Pharmacophore Development</b>	<b>213</b>
	<i>Osman F. Güner, Marvin Waldman, Rémy Hoffmann, and Jong-Hoon Kim</i>	
12.1.	Introduction	<b>215</b>
12.2.	Methods	<b>217</b>
12.3.	Results and Discussion	<b>217</b>
12.3.1.	Use of Query Clustering and Merging	217
12.3.2.	Receptor-Based versus Ligand-Based Pharmacophore Models	221
12.3.3.	Use of Shape versus Pharmacophore versus Merged Pharmacophore/Shape Queries	223
12.3.4.	The Significance of Training Set Selection: Using Similar versus Diverse Compounds	227
12.3.5.	Manual versus Automated Pharmacophore Model Generation	230
12.3.6.	Rigid versus Flexible Searching	231
<b>13.</b>	<b>Pharmacophore Modeling by Automated Methods: Possibilities and Limitations</b>	<b>237</b>
	<i>Morten Langgård, Berith Bjørnholm, and Klaus Gundertofte</i>	
13.1.	Introduction	<b>239</b>
13.1.1.	Pharmacophore Models	240
13.2.	The Methods	<b>241</b>
13.2.1.	Flo96	241
13.2.2.	Catalyst	243
13.3.	Results and Discussion	<b>244</b>
13.3.1.	Flo96	244
13.3.2.	Catalyst	246
13.4.	Conclusion	<b>249</b>
<b>14.</b>	<b>Database Mining Using Pharmacophore Models to Discover Novel Structural Prototypes</b>	<b>251</b>
	<i>James J. Kaminski, Dinanath. F. Rane, and Marnie L. Rothofsky</i>	
<b>15.</b>	<b>Predicting Drug-Drug Interactions in Silico Using Pharmacophores: Paradigm for the Next Millennium</b>	<b>269</b>
	<i>Sean Ekins, Barbara J. Ring, Gianpaolo Bravi, James H. Wikel, and Steven A. Wrighton</i>	
15.1.	Introduction	<b>271</b>
15.2.	Shifting the Drug Metabolism Paradigm	<b>273</b>
15.3.	Cytochrome P450 Pharmacophore Modeling Methodology	<b>278</b>
15.4.	Utilizing and Interpreting Data Generated by Computational Models for Enzymes and Transporters Involved in Drug Metabolism	<b>282</b>
15.5.	The Challenge Ahead	<b>286</b>
15.6.	Concluding Remarks	<b>288</b>
<b>16.</b>	<b>Feature-Based Pharmacophores: Application to Some Biological Systems</b>	<b>301</b>
	<i>Rémy. Hoffmann, Hong Li, and Thierry Langer</i>	
16.1.	Introduction	<b>303</b>

16.2.	First Case: TXSI-TXRA	<b>304</b>
16.2.1.	Introduction	304
16.2.2.	Methods	305
16.2.3.	Results and Discussion	306
16.3.	Second Case: Retinoic Acid Receptor Ligands	<b>307</b>
16.3.1.	Introduction	307
16.3.2.	Training Set and Methods	308
16.3.3.	Results and Discussion	310
16.4.	Third Case: Feature-Based Pharmacophores Derived from Structural Information	<b>312</b>
16.4.1.	Introduction	312
16.4.2.	Methods	313
16.4.3.	Results and Discussion	315
16.4.4.	Mapping the Chemical Features on the Active Conformation of Methotrexate	316
16.5.	Conclusion	<b>316</b>
<b>17.</b>	<b>Receptor-Based Pharmacophore Perception and Modeling</b>	<b>339</b>
	<i>C. M. Venkatachalam, Paul Kirchoff, and Marvin Waldman</i>	
17.1.	Introduction	<b>321</b>
17.2.	Pharmacophore Definition	<b>322</b>
17.3.	Retinoid Series 1	<b>327</b>
17.4.	Retinoid Series 2	<b>328</b>
17.5.	Retinoid Series 3	<b>329</b>
17.6.	Pharmacophore Validation	<b>331</b>
17.7.	Conclusions	<b>333</b>
<b>Part III.</b>	<b>RECEPTOR-BASED PHARMACOPHORES</b>	<b>337</b>
<b>18.</b>	<b>Receptor-Based Pharmacophore Perception and Modeling</b>	<b>339</b>
	<i>C. M. Venkatachalam, Paul Kirchoff, and Marvin Waldman</i>	
18.1.	Introduction	<b>341</b>
18.2.	Cerius2 Structure-Based Focusing Method	<b>342</b>
18.2.1.	Active Site	343
18.2.2.	Ludi Interaction Map	344
18.2.3.	Cluster Analysis of the Interaction Map	344
18.2.4.	Multiples Queries	345
18.2.5.	Volume Exclusions	345
18.2.6.	Catalyst Database Search	346
18.3.	Results and Discussion for the Estrogen Binding	<b>346</b>
<b>19.</b>	<b>Pharmacophore-Based Molecular Docking</b>	<b>351</b>
	<i>Bert E. Thomas IV, Diane Joseph-McCarthy, and Juan C. Alvarez</i>	
19.1.	Introduction	<b>353</b>
19.2.	The Dock Algorithm	<b>355</b>
19.2.1.	Conformational Ensemble Docking	356
19.3.	Pharmacophore-Based Docking	<b>357</b>
19.3.1.	Database Preparation	360
19.3.2.	Site Point Generation	361
19.3.3.	Validation	361

19.4. Discussion	362
<b>Applications in Drug Design</b>	<b>369</b>
<b>20. The Use of Multiple Excluded Volumes Derived from X-Ray Crystallographic Structures in 3D Database</b>	
<b>Searching and 3D QSAR</b>	<b>371</b>
<i>Mikael Gillner and Paulette Greenidge</i>	
20.1. Introduction	373
20.2. Background	374
20.3. Methods	376
20.3.1. Catalyst Pharmacophore Construction and 3D QSAR	376
20.4. Results and Discussion	378
20.5. Conclusion	382
<b>21. Docking-Derived Pharmacophores from Models of Receptor-Ligand Complexes</b>	<b>385</b>
<i>Renate Griffith, John B. Bremner, and Burak Coban</i>	
21.1. Introduction	387
21.2. Agonist and Antagonist Binding Site(s) on the Adrenergic Receptors	389
21.3. 3D Model Building and Docking	391
21.3.1. Revision of the Models	394
21.3.2. Docking of Adrenaline	395
21.3.3. Docking of a Rigid Antagonist (IQC)	397
21.4. Construction of Docking-Derived Pharmacophores	398
21.4.1. The $\alpha$ 1A Pharmacophore	399
21.4.2. The $\alpha$ 1B pharmacophore	400
21.4.3. Comparing the Docking-Derived Pharmacophores	400
21.4.4. Design of Potentially $\alpha$ 1B-Selective Ligands	401
<b>22. Technique for Developing a Pharmacophore Model that Accommodates Inherent Protein Flexibility: An Application to HIV-1 Integrase</b>	<b>409</b>
<i>Kevin M. Masukawa, Heather A. Carlson, and J. Andrew McCammon</i>	
22.1. Introduction	411
22.2. Computational Details	413
22.2.1. The MD Simulation and Preparation of the Available Crystal Structures	413
22.2.2. MUSIC	414
22.2.3. The Dynamic Pharmacophore Model for HIV-1 Integrase	415
22.2.4. Static Pharmacophore Models	418
22.2.5. Using the Catalyst Programs	418
22.3. Results and Discussion	420
22.4. Conclusion	423
<b>Part IV. NEW ALGORITHMS IN PHARMACOPHORE DEVELOPMENT</b>	<b>429</b>
<b>23. Pharmacophores Derived from the 3D Substructure Perception</b>	<b>431</b>
<i>Sandra Handschuh and Johann Gasteiger</i>	
23.1. Introduction	433
23.2. General Principles of the Genetic Algorithm	434
23.2.1. Encoding of the Individuals	436

23.2.2.	Optimization Criteria	437
23.2.3.	The Genetic and Nongenetic Operators—A Short Description	438
23.2.4.	The Pareto Fitness of Individuals	442
23.3.	Matching the Conformations—Directed Tweak	<b>444</b>
23.4.	Special Features of the Program	<b>447</b>
23.4.1.	Close Contact Check of van der Waals Radii	447
23.4.2.	Matching Criteria	447
23.4.3.	Superimposition Restrictions	449
23.5.	Summary	<b>450</b>
<b>24.</b>	<b>The Electron-Conformational Method of Identification of Pharmacophore and Anti Pharmacophore Shielding</b>	<b>455</b>
	<i>Isaac B. Bersuker, Süleyman Bahçeci, and James E. Boggs</i>	
24.1.	Introduction: Improved Definition of Pharmacophore	<b>457</b>
24.2.	Description by EC Matrices and Pharmacophore Identification	<b>459</b>
24.3.	Anti-Pharmacophore Shielding and Other Auxiliary Groups. Formula of Activity	<b>462</b>
24.4.	Parameterization and Results	<b>464</b>
24.4.1.	Angiotensin Converting Enzyme (ACE) Inhibitors	466
24.4.2.	Rice Blast Activity (RBA)	470
24.5.	Conclusions	<b>472</b>
<b>25.</b>	<b>Development and Optimization of Property-Based Pharmacophores</b>	<b>477</b>
	<i>Ali G. Özkabak, Mitchell A. Miller, and Douglas R. Henry</i>	
25.1.	Introduction	<b>479</b>
25.2.	Flexible Substructure- or Field-Based Superposition of Structures	<b>482</b>
25.3.	Identification of Relevant Functional and Physicochemical Property Groups	<b>484</b>
25.4.	Generating an Initial Pharmacophore	<b>487</b>
25.5.	Optimizing the Pharmacophore	<b>490</b>
25.6.	Summary	<b>493</b>
<b>26.</b>	<b>Effect of Variable Weights and Tolerances on Predictive Model Generation</b>	<b>499</b>
	<i>Jon Sutter, Osman Güner, Rémy Hoffmann, Hong Li, and Marvin Waldman</i>	
26.1.	Background	<b>501</b>
26.2.	Methodology	<b>502</b>
26.3.	Cost Function	504
26.4.	Case Study	<b>506</b>
26.5.	Conclusions	<b>510</b>
<b>PART V.</b>	<b>THE FUTURE OF PHARMACOPHORE RESEARCH</b>	<b>513</b>
<b>27.</b>	<b>Future Directions In Pharmacophore Discovery</b>	<b>515</b>
	<i>John H. Van Drie</i>	
27.1.	Introduction	<b>517</b>
27.2.	Goals for a Pharmacophore Discovery Method	<b>520</b>
27.2.1.	Objectivity	520
27.2.2.	Completeness	521
27.2.3.	Robustness	522

27.2.4.	Computational Controls	523
27.2.5.	Statistical Measures of Quality	524
27.2.6.	Prospective Applications of Pharmacophores	524
27.3.	Not All Datasets Are Created Equal	<b>525</b>
27.4.	Conformational Analysis	<b>526</b>
27.5.	Frontiers	<b>527</b>
<b>Index</b>	<b>531</b>	